Similarly, empagliflozin, an SGLT-2 inhibitor, has been shown to improve liver steatosis in T2DM patients with NAFLD or nonalcoholic steatohepatitis (NASH) [15–18]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.